Dissolution of poorly water-soluble drugs in biphasic media using USP 4 and fiber optic system

References

• Levy G. Effect of dissolution rate on absorption, metabolism, and pharmacological activity of drugs. J Mond Pharm. 1967;3:237–254.
   Google Scholar
• Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res. 1988;15:11–22.
   Google Scholar
• Guidance for industry. Conduct of bioavailability and bioequivalence studies—Part A: Oral dosage formulations for systemic effects. Health Canada, 1992.
   Google Scholar
• “USP General Chapter <1088> - In-vitro and in-vivo evaluation of dosage forms”, 2004. United States Pharmacopeia and National Formulary, United States Pharmacopeial Convention, Inc., 29th edition:2513–2518.
   Google Scholar
• Rohrs BR. Dissolution method development for poorly water soluble compounds. Dissolution technologies. 2001;8:1–5.
   Google Scholar
• Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate experiments. J Pharm Sci. 1967;56:1238–1242.
   PubMed Web of Science ®Google Scholar
• USP General Chapter <711> Dissolution of solid oral dosage forms. 2004. United States Pharmacopeia and National Formulary, United States Pharmacopeial Convention, Inc., 29th edition, 2004.
   Google Scholar
• Grundy JS, Anderson KE, Rogers JA, Foster RT. Studies on dissolution testing of the Nifedipine gastrointestinal therapeutic system. I. Description of two-phase in-vitro dissolution test. J of Controlled Release. 1997;48:1–8.
   Web of Science ®Google Scholar
• Pillay V, Fassihi R. A new method for dissolution studies of lipid-filled capsules employing Nifedipine as a model drug. Pharm Res. 1999;16(2):333–337.
   PubMed Web of Science ®Google Scholar
• Chaudhary RS, Gangwal SS, Gupta VK, Shah YN, Jindal KC, Khanna AS. Dissolution system for nifedipine sustained release formulations. Drug Dev Ind Pharm. 1994;20(7):1267–1274.
   Web of Science ®Google Scholar
• Qureshi SA, Caille G, Brien R, Piccirilli G, Yu V, Mcgilveray IJ. Application of flow-through dissolution method for the evaluation of oral formulations of Nifedipine. Drug Dev Ind Pharm. 1994;20(11):1869–1882.
   Web of Science ®Google Scholar
• Bak A, Gore A, Yanez E et al. The co-crystal approach to improve the exposure of an insoluble compound—AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J Pharm Sci. 2008;23:1–15.
   Google Scholar
• Doherty EM, Bannon AW, Bo Y et al. Novel vanilloid receptor-1 antagonists: Structure-activity relationships in the ‘‘A-region’’ and the selection of a clinical candidate, AMG 517. J Med Chem. 2007;50:3515–3527.
   PubMed Web of Science ®Google Scholar
• Yanez E, Daurio D, Buntich S, Bak A. Physicochemical, solid-state, and pharmacokinetic properties of AMG 517 free base. 2005. Unpublished work.
   Google Scholar
• Electronic orange book, Approved drug products with therapeutic equivalence evaluations (http://www.fda.gov/cder/ob/).
   Google Scholar
• Almarsson ö,Zaworotko MJ. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem Commun. 2004;17:1889–1896.
   PubMed Web of Science ®Google Scholar
• Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci. 1964;53:1392–1403.
   PubMed Web of Science ®Google Scholar
• Dissolution tests to predict bioavailability of drugs, 5th International Workshop on Physical Characterization of Pharmaceutical Solids, June 24, 2004, Sandra Klein, Institute of Pharmaceutical Technology, Johann Wolfgang Goethe University, Frankfurt.
   Google Scholar
• Stead JA, Freeman M, John EG, Ward GT, Whiting B. Ibuprofen tablets: Dissolution and bioavailability studies. Int J Pharm. 1983;14:59–72.
   Web of Science ®Google Scholar
• Dressman, JB, 1995; Physiological aspects of the design of dissolution tests. Capsugel seminar, USA.
   Google Scholar
• Yunzhe S, Yang R, Zhou W and Xing T. Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. Int J Pharm. 2008;359:144–149.
   PubMed Web of Science ®Google Scholar
• Cardot JM, Beyssac E, and Alric M. In vitro–in vivo correlation: Importance of dissolution in IVIVC. Dissolution Technologies. 2007;2:15–19.
   Google Scholar
• Stanton MK and Bak A. Physicochemical properties of pharmaceutical co-crystals: A case study of ten AMG 517 co-crystals. Cryst. Growth Des. 2008;8:3856–3862.
   Web of Science ®Google Scholar
• Krowczynski L. Pharmazie. 1978;33:241–247.
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations. J Pharm Sci. 1967;56:1238–1242.
   PubMed Web of Science ®Google Scholar
• Grundy JS, Anderson KE, Rogers JA, Fosterb TF. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. I. Description of a two-phase in vitro dissolution test. J Controlled Release. 1997;48:9–17.
   Web of Science ®Google Scholar
• Phillips JG, Chen Y, Wakeling IN. A flow-through dissolution approach to in vivo/in vitro correlation of adinazolam release from sustained release formulations. Drug Dev Ind Pharm. 1989;15:2177–2195.
   Web of Science ®Google Scholar
• Porges E, Schade B, Ropte W. Automated flow-through method to determine the dissolution rate of slightly soluble substances. Pharm Ind. 1985;47:77–86.
   Web of Science ®Google Scholar
• Sunesen VH, Pedersen BL, Kristensen HG, Mullertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur J Pharm Sci. 2005;24:305–313.
   PubMed Web of Science ®Google Scholar